Posted: June 24, 2020
Paul G. Kluetz, MD, has been named the FDA’s new Deputy Director of the OCE. During his 10 years with the FDA, Dr. Kluetz founded the OCE’s Patient-Focused Drug Development program. The IASLC looks forward to our continued collaboration and partnership with the FDA with regard to lung cancer therapies, diagnostics, and policies, such as major pathologic response and smoking cessation.
